IX BIOPHARMA LTD.
(Incorporated in the Republic of Singapore)
Company Registration No. 200405621W

ISSUANCE AND ALLOTMENT OF DIRECTORS' SHARES AND SUBSCRIPTION SHARES

The Board of Directors (the "**Board**") of iX Biopharma Ltd. (the "**Company**", and together with its subsidiaries, the "**Group**") refers to its announcements dated 16 April 2026, 23 April 2026, 30 April 2026 and 8 May 2026 and circular dated 23 April 2026 (the "**Circular**") in relation to the Proposed Placements.

Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in the Circular.

The Board wishes to announce the following issuance and allotments of shares today:

1. Directors' Shares

Name (Designation)	**No. of Directors' Shares**
Mr. Patrick Donald Davies (Lead Independent Director)	106,168
Mr. Teo Woon Keng John (Independent Director)	99,051
Mr. Albert Ho Shing Tung (Non-Executive Non-Independent Director)	99,051
Total	**304,270**

2. Subscription Shares

Substantial Shareholder	**No. of Subscription Shares**
Anson Properties Pte Ltd	1,045,164

The Directors' Shares and the Subscription Shares rank *pari passu* in all respects with the existing shares of the Company.

The Directors' Shares and the Subscription Shares are expected to be listed and quoted on the SGX-ST on or around 15 May 2026, and trading is expected to commence with effect from 9.00 a.m. on the same date.

Following the allotment and issuance of Directors' Shares and Subscription Shares, as well as the allotment and issuance of 4,068,186 new shares pursuant to the vesting of share awards under the iX Performance Share Plan which was announced separately today, the total number of issued shares of the Company has increased from 1,051,239,596 Shares to 1,056,657,215 Shares.

BY ORDER OF THE BOARD

Gwendolin Lee Soo Fern/Lai Kuan Loong, Victor
Company Secretaries
13 May 2026

---

*This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "**Sponsor**").*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone (65) 6590 6881.